432 related articles for article (PubMed ID: 9815553)
21. Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group.
George RE; Variend S; Cullinane C; Cotterill SJ; McGuckin AG; Ellershaw C; Lunec J; Pearson AD;
Med Pediatr Oncol; 2001 Jan; 36(1):169-76. PubMed ID: 11464876
[TBL] [Abstract][Full Text] [Related]
22. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.
Oberthuer A; Hero B; Spitz R; Berthold F; Fischer M
Clin Cancer Res; 2004 Jul; 10(13):4307-13. PubMed ID: 15240516
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of MDR1 gene expression in neuroblastoma: results of a multivariate analysis.
Bénard J; Bourhis J; de Vathaire F; Ferrandis E; Terrier-Lacombe MJ; Lemerle J; Riou G; Hartmann O
Prog Clin Biol Res; 1994; 385():111-6. PubMed ID: 7972202
[TBL] [Abstract][Full Text] [Related]
24. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
London WB; Castleberry RP; Matthay KK; Look AT; Seeger RC; Shimada H; Thorner P; Brodeur G; Maris JM; Reynolds CP; Cohn SL
J Clin Oncol; 2005 Sep; 23(27):6459-65. PubMed ID: 16116153
[TBL] [Abstract][Full Text] [Related]
25. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma.
Squire JA; Thorner PS; Weitzman S; Maggi JD; Dirks P; Doyle J; Hale M; Godbout R
Oncogene; 1995 Apr; 10(7):1417-22. PubMed ID: 7731693
[TBL] [Abstract][Full Text] [Related]
26. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study.
Cohn SL; Look AT; Joshi VV; Holbrook T; Salwen H; Chagnovich D; Chesler L; Rowe ST; Valentine MB; Komuro H
Cancer Res; 1995 Feb; 55(4):721-6. PubMed ID: 7850780
[TBL] [Abstract][Full Text] [Related]
27. In vitro effects of MYCN sense and antisense expression in MYCN-amplified human neuroblastoma cells.
Kavallaris M; Gardaneh M; Cheung B; Camacho ML; Hocker JE; Norris MD; Haber M; Marshall GM
Anticancer Res; 1998; 18(3A):1793-7. PubMed ID: 9673406
[TBL] [Abstract][Full Text] [Related]
28. Neuroblastoma in the first year of life: clinical and biologic factors influencing outcome.
Grosfeld JL; Rescorla FJ; West KW; Goldman J
Semin Pediatr Surg; 1993 Feb; 2(1):37-46. PubMed ID: 8062021
[TBL] [Abstract][Full Text] [Related]
29. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
[TBL] [Abstract][Full Text] [Related]
30. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease.
Mora J; Cheung NK; Chen L; Qin J; Gerald W
Cancer; 2001 Jan; 91(2):435-42. PubMed ID: 11180092
[TBL] [Abstract][Full Text] [Related]
31. N-myc amplification and cell proliferation rate in human neuroblastoma.
Pession A; Trerè D; Perri P; Rondelli R; Montanaro L; Mantovani W; Derenzini M; Paolucci G
J Pathol; 1997 Nov; 183(3):339-44. PubMed ID: 9422991
[TBL] [Abstract][Full Text] [Related]
32. N-myc protein expression in human breast carcinoma: prognostic implications.
Mizukami Y; Nonomura A; Takizawa T; Noguchi M; Michigishi T; Nakamura S; Ishizaki T
Anticancer Res; 1995; 15(6B):2899-905. PubMed ID: 8669886
[TBL] [Abstract][Full Text] [Related]
33. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma.
Bourhis J; De Vathaire F; Wilson GD; Hartmann O; Terrier-Lacombe MJ; Boccon-Gibod L; McNally NJ; Lemerle J; Riou G; Bénard J
Cancer Res; 1991 Jan; 51(1):33-6. PubMed ID: 1988094
[TBL] [Abstract][Full Text] [Related]
34. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma.
Chan HS; Haddad G; Thorner PS; DeBoer G; Lin YP; Ondrusek N; Yeger H; Ling V
N Engl J Med; 1991 Dec; 325(23):1608-14. PubMed ID: 1682809
[TBL] [Abstract][Full Text] [Related]
35. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.
Seeger RC; Brodeur GM; Sather H; Dalton A; Siegel SE; Wong KY; Hammond D
N Engl J Med; 1985 Oct; 313(18):1111-6. PubMed ID: 4047115
[TBL] [Abstract][Full Text] [Related]
36. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma.
Gehring M; Berthold F; Edler L; Schwab M; Amler LC
Cancer Res; 1995 Nov; 55(22):5366-9. PubMed ID: 7585602
[TBL] [Abstract][Full Text] [Related]
37. Expressions of N-myc and ras oncogene products in neuroblastoma and their correlations with prognosis.
Nakada K; Fujioka T; Kitagawa H; Takakuwa T; Yamate N
Jpn J Clin Oncol; 1993 Jun; 23(3):149-55. PubMed ID: 8350488
[TBL] [Abstract][Full Text] [Related]
38. The characteristics of mediastinal neuroblastoma.
Suita S; Tajiri T; Sera Y; Takamatsu H; Mizote H; Ohgami H; Kurosaki N; Hara T; Okamura J; Miyazaki S; Sugimoto T; Kawakami K; Tsuneyoshi M; Tasaka H; Yano H; Akiyama H; Ikeda K
Eur J Pediatr Surg; 2000 Dec; 10(6):353-9. PubMed ID: 11215774
[TBL] [Abstract][Full Text] [Related]
39. Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas.
Nakagawara A; Kadomatsu K; Sato S; Kohno K; Takano H; Akazawa K; Nose Y; Kuwano M
Cancer Res; 1990 May; 50(10):3043-7. PubMed ID: 2185879
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma.
Bordow SB; Norris MD; Haber PS; Marshall GM; Haber M
J Clin Oncol; 1998 Oct; 16(10):3286-94. PubMed ID: 9779703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
